These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

736 related items for PubMed ID: 9321737

  • 1. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
    Prichard BN, Owens CW, Graham BR.
    J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737
    [Abstract] [Full Text] [Related]

  • 2. Moxonidine: a new antiadrenergic antihypertensive agent.
    Prichard BN, Graham BR, Owens CW.
    J Hypertens Suppl; 1999 Aug; 17(3):S41-54. PubMed ID: 10489098
    [Abstract] [Full Text] [Related]

  • 3. Effective antihypertensive therapy: blood pressure control with moxonidine.
    Prichard BN, Graham BR.
    J Cardiovasc Pharmacol; 1996 Aug; 27 Suppl 3():S38-48. PubMed ID: 8872298
    [Abstract] [Full Text] [Related]

  • 4. Selective antihypertensive action of moxonidine is mediated mainly by I1-imidazoline receptors in the rostral ventrolateral medulla.
    Haxhiu MA, Dreshaj I, Schäfer SG, Ernsberger P.
    J Cardiovasc Pharmacol; 1994 Aug; 24 Suppl 1():S1-8. PubMed ID: 7533221
    [Abstract] [Full Text] [Related]

  • 5. The use of moxonidine in the treatment of hypertension.
    Prichard BN, Graham BR.
    J Hypertens Suppl; 1997 Jan; 15(1):S47-55. PubMed ID: 9050986
    [Abstract] [Full Text] [Related]

  • 6. Role of medullary I1-imidazoline and alpha 2-adrenergic receptors in the antihypertensive responses evoked by central administration of clonidine analogs in conscious spontaneously hypertensive rats.
    Buccafusco JJ, Lapp CA, Westbrooks KL, Ernsberger P.
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1162-71. PubMed ID: 7791087
    [Abstract] [Full Text] [Related]

  • 7. Moxonidine, a centrally acting antihypertensive agent, is a selective ligand for I1-imidazoline sites.
    Ernsberger P, Damon TH, Graff LM, Schäfer SG, Christen MO.
    J Pharmacol Exp Ther; 1993 Jan; 264(1):172-82. PubMed ID: 8380858
    [Abstract] [Full Text] [Related]

  • 8. The renaissance of centrally acting antihypertensive drugs.
    van Zwieten PA.
    J Hypertens Suppl; 1999 Aug; 17(3):S15-21. PubMed ID: 10489094
    [Abstract] [Full Text] [Related]

  • 9. I1 imidazoline agonists. General clinical pharmacology of imidazoline receptors: implications for the treatment of the elderly.
    Prichard BN, Graham BR.
    Drugs Aging; 2000 Aug; 17(2):133-59. PubMed ID: 10984201
    [Abstract] [Full Text] [Related]

  • 10. Why imidazoline receptor modulator in the treatment of hypertension?
    Schäfer SG, Kaan EC, Christen MO, Löw-Kröger A, Mest HJ, Molderings GJ.
    Ann N Y Acad Sci; 1995 Jul 12; 763():659-72. PubMed ID: 7677385
    [Abstract] [Full Text] [Related]

  • 11. A novel mechanism of action for hypertension control: moxonidine as a selective I1-imidazoline agonist.
    Ernsberger P, Haxhiu MA, Graff LM, Collins LA, Dreshaj I, Grove DL, Graves ME, Schäfer SG, Christen MO.
    Cardiovasc Drugs Ther; 1994 Mar 12; 8 Suppl 1():27-41. PubMed ID: 8068578
    [Abstract] [Full Text] [Related]

  • 12. Imidazoline receptors associated with noradrenergic terminals in the rostral ventrolateral medulla mediate the hypotensive responses of moxonidine but not clonidine.
    Chan CK, Burke SL, Zhu H, Piletz JE, Head GA.
    Neuroscience; 2005 Mar 12; 132(4):991-1007. PubMed ID: 15857704
    [Abstract] [Full Text] [Related]

  • 13. Interruption of central neuronal pathway of imidazoline I1 receptor mediates the hypertensive effect of cyclosporine in rats.
    El-Mas MM, Omar AG, Helmy MM, Mohy El-Din MM.
    Brain Res; 2009 Jan 12; 1248():96-106. PubMed ID: 19028461
    [Abstract] [Full Text] [Related]

  • 14. General pharmacology of the novel centrally acting antihypertensive agent moxonidine.
    Armah BI, Hofferber E, Stenzel W.
    Arzneimittelforschung; 1988 Oct 12; 38(10):1426-34. PubMed ID: 3196383
    [Abstract] [Full Text] [Related]

  • 15. Sympathoexcitation of moxonidine in the caudal ventrolateral medulla is dependent on I1-imidazoline receptors in anesthetized rats.
    Wang LG, Gao L, Wang W, Yuan WJ, Wang WZ.
    Neurosci Lett; 2007 Oct 16; 426(2):91-6. PubMed ID: 17889438
    [Abstract] [Full Text] [Related]

  • 16. Pharmacology of moxonidine, an I1-imidazoline receptor agonist.
    Ziegler D, Haxhiu MA, Kaan EC, Papp JG, Ernsberger P.
    J Cardiovasc Pharmacol; 1996 Oct 16; 27 Suppl 3():S26-37. PubMed ID: 8872297
    [Abstract] [Full Text] [Related]

  • 17. Comparative study of NMDA and AMPA/kainate receptors involved in cardiovascular inhibition produced by imidazoline-like drugs in anaesthetized rats.
    Wang LG, Zeng J, Yuan WJ, Su DF, Wang WZ.
    Exp Physiol; 2007 Sep 16; 92(5):849-58. PubMed ID: 17573415
    [Abstract] [Full Text] [Related]

  • 18. Clinical experience with moxonidine.
    Prichard BN.
    Cardiovasc Drugs Ther; 1994 Mar 16; 8 Suppl 1():49-58. PubMed ID: 8068579
    [Abstract] [Full Text] [Related]

  • 19. Influence of central inhibition of sympathetic nervous activity on myocardial metabolism in chronic heart failure: acute effects of the imidazoline I1-receptor agonist moxonidine.
    Mobini R, Fu M, Jansson PA, Bergh CH, Scharin Täng M, Waagstein F, Andersson B.
    Clin Sci (Lond); 2006 Mar 16; 110(3):329-36. PubMed ID: 16209659
    [Abstract] [Full Text] [Related]

  • 20. I1-imidazoline-receptor agonists in the treatment of hypertension: an appraisal of clinical experience.
    Ollivier JP, Christen MO.
    J Cardiovasc Pharmacol; 1994 Mar 16; 24 Suppl 1():S39-48. PubMed ID: 7533226
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.